{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:33:38Z","timestamp":1787045618056,"version":"build-2736575974"},"reference-count":78,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Most translational work on bacteriophages has focused on antibacterial therapy or food biocontrol. A third use case is scientifically plausible but remains insufficiently defined: the intentional use of characterized phages to modulate gut microbial communities without infection-treatment claims. In this review, the term \u201cphagobiotics\u201d is used for defined, purified and process-controlled bacteriophages or phage cocktails intended for selective gut microbiota modulation. The concept is evaluated across natural human phage exposure, the gut phageome, mechanisms of phage-mediated community modulation, human intervention studies, preclinical models, manufacturing quality and regulatory boundaries. Current evidence supports biological plausibility and indicates that oral phage exposure can be well tolerated and, in some contexts, can selectively affect target bacterial groups without broad microbiota disruption. Generalized clinical efficacy and broad microbiome-support claims, however, remain insufficiently established. Microbiological-modulation claims require target-linked evidence, whereas claims to treat, prevent or cure disease or replace antibiotics fall outside the proposed non-therapeutic category. A proportionate framework is proposed in which natural exposure and food-use precedents inform, but do not determine, the safety rationale; product-specific controls focus on identity, purity, production-host control, manufacturing consistency, stability, genomic characterization and claim-linked evidence. Regulatory classification remains case-specific and depends on intended use, product format, target population and claims.<\/jats:p>","DOI":"10.3390\/v18080907","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:06:41Z","timestamp":1787044001000},"page":"907","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bacteriophages as Phagobiotics: Scientific Rationale and Translational Boundaries for Gut Microbiome Modulation"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7947-1128","authenticated-orcid":false,"given":"Fedor","family":"Zurabov","sequence":"first","affiliation":[{"name":"Research and Production Center Micromir, 5\/23 b1, Nizhniy Kiselniy Ln., Moscow 107031, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.chom.2019.01.017","article-title":"Bacteriophages of the human gut: The known unknown of the microbiome","volume":"25","author":"Shkoporov","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Zuppi, M., Hendrickson, H.L., O\u2019Sullivan, J.M., and Vatanen, T. (2022). Phages in the gut ecosystem. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.822562"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41586-025-09786-2","article-title":"Long-read metagenomics reveals phage dynamics in the human gut microbiome","volume":"649","author":"Wirbel","year":"2026","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2481178","DOI":"10.1080\/19490976.2025.2481178","article-title":"Effects of bacteriophages on gut microbiome functionality","volume":"17","author":"Kurilovich","year":"2025","journal-title":"Gut Microbes"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.chom.2019.01.014","article-title":"Phage therapy: A renewed approach to combat antibiotic-resistant bacteria","volume":"25","author":"Kortright","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Fuerst-Wilmes, M., Respondek, V., Schramm, M., Lilienthal, N., Buss, K., and Duechting, A. (2025). Regulation of phage therapy medicinal products: Developments, challenges, and opportunities. Front. Cell. Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1631359"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Fukaya-Shiba, A., Ogata, A., Kuribayashi, R., Sakurai, A., Suzuki, K., Takadama, S., Nishimura, J., Uchiyama, J., Ohge, H., and Takeuchi, T. (2025). Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1713471"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Moye, Z.D., Woolston, J., and Sulakvelidze, A. (2018). Bacteriophage applications for food production and processing. Viruses, 10.","DOI":"10.3390\/v10040205"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"863945","DOI":"10.1155\/2012\/863945","article-title":"Bacteriophages and their role in food safety","volume":"2012","author":"Sillankorva","year":"2012","journal-title":"Int. J. Microbiol."},{"key":"ref_10","unstructured":"U.S. Food and Drug Administration (2006). Food additives permitted for direct addition to food for human consumption; bacteriophage preparation. Fed. Regist., 71, 47729\u201347732."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Hill","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrgastro.2017.75","article-title":"Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the definition and scope of prebiotics","volume":"14","author":"Gibson","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41575-020-0344-2","article-title":"The International Scientific Association for Probiotics and Prebiotics consensus statement on the definition and scope of synbiotics","volume":"17","author":"Swanson","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41575-021-00440-6","article-title":"The International Scientific Association for Probiotics and Prebiotics consensus statement on the definition and scope of postbiotics","volume":"18","author":"Salminen","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_15","unstructured":"U.S. Food and Drug Administration (2026, June 30). Structure\/Function Claims, Available online: https:\/\/www.fda.gov\/food\/nutrition-food-labeling-and-critical-foods\/structurefunction-claims."},{"key":"#cr-split#-ref_16.1","unstructured":"European Parliament and Council (2006). Regulation"},{"key":"#cr-split#-ref_16.2","unstructured":"(EC) No. 1924\/2006 on nutrition and health claims made on foods. Off. J. Eur. Union, L404, 9-25."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.chom.2023.11.015","article-title":"Infant gut DNA bacteriophage strain persistence during the first 3 years of life","volume":"32","author":"Lou","year":"2024","journal-title":"Cell Host Microbe"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00431-025-06173-x","article-title":"Phage diversity in human breast milk: A systematic review","volume":"184","author":"Guo","year":"2025","journal-title":"Eur. J. Pediatr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41522-026-00941-9","article-title":"Mining of food metagenomes reveals an unexplored diversity of dsDNA bacteriophages","volume":"12","author":"Walsh","year":"2026","journal-title":"npj Biofilms Microbiomes"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41564-024-01906-4","article-title":"Longitudinal phage-bacteria dynamics in the early life gut microbiome","volume":"10","author":"Tisza","year":"2025","journal-title":"Nat. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1016\/j.cell.2024.07.039","article-title":"Unexplored microbial diversity from 2,500 food metagenomes and links with the human microbiome","volume":"187","author":"Carlino","year":"2024","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Febvre, H.P., Rao, S., Gindin, M., Goodwin, N.D.M., Finer, E., Vivanco, J.S., Lu, S., Manter, D.K., Wallace, T.C., and Weir, T.L. (2019). PHAGE Study: Effects of supplemental bacteriophage intake on inflammation and gut microbiota in healthy adults. Nutrients, 11.","DOI":"10.3390\/nu11030666"},{"key":"ref_23","unstructured":"U.S. Code of Federal Regulations (2026, July 01). 21 CFR \u00a7 172.785. Listeria-Specific Bacteriophage Preparation, Available online: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-B\/part-172\/subpart-H\/section-172.785."},{"key":"ref_24","unstructured":"U.S. Food and Drug Administration (2026, June 30). GRAS Notice Inventory, Available online: https:\/\/www.cfsanappsexternal.fda.gov\/scripts\/fdcc\/index.cfm?set=GRASNotices."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"EFSA BIOHAZ Panel (2016). Evaluation of the safety and efficacy of Listex P100 for reduction of pathogens on different ready-to-eat food products. EFSA J., 14, 4565.","DOI":"10.2903\/j.efsa.2016.4565"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s11095-014-1617-7","article-title":"Quality and safety requirements for sustainable phage therapy products","volume":"32","author":"Pirnay","year":"2015","journal-title":"Pharm. Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Grubb, D.S., Wrigley, S.D., Freedman, K.E., Wei, Y., Vazquez, A.R., Trotter, R.E., Wallace, T.C., Johnson, S.A., and Weir, T.L. (2020). PHAGE-2 Study: Supplemental bacteriophages extend Bifidobacterium animalis subsp. lactis BL04 benefits on gut health and microbiota in healthy adults. Nutrients, 12.","DOI":"10.20944\/preprints202007.0338.v1"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ebiom.2015.12.023","article-title":"Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: A randomized trial in children from Bangladesh","volume":"4","author":"Sarker","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1038\/s41467-023-41329-z","article-title":"Phage-microbe dynamics after sterile faecal filtrate transplantation in individuals with metabolic syndrome: A double-blind, randomised, placebo-controlled clinical trial assessing efficacy and safety","volume":"14","author":"Wortelboer","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s44259-025-00117-z","article-title":"Re-evaluating what makes a phage unsuitable for therapy","volume":"3","author":"Cook","year":"2025","journal-title":"npj Antimicrob. Resist."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1038\/s41467-024-52450-y","article-title":"Prophage-encoded antibiotic resistance genes are enriched in human-impacted environments","volume":"15","author":"Liao","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_32","unstructured":"European Medicines Agency (2026, July 01). Guideline on Quality Aspects of Phage Therapy Medicinal Products. EMA\/CHMP\/BWP\/1\/2024, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-quality-aspects-phage-therapy-medicinal-products_en.pdf."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/femsre\/fuv048","article-title":"Computational approaches to predict bacteriophage-host relationships","volume":"40","author":"Edwards","year":"2016","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1093\/nar\/gkab133","article-title":"Streamlining CRISPR spacer-based bacterial host predictions to decipher the viral dark matter","volume":"49","author":"Dion","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Human Microbiome Project Consortium (2012). Structure, function and diversity of the healthy human microbiome. Nature, 486, 207\u2013214.","DOI":"10.1038\/nature11234"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4161\/bact.21868","article-title":"Bacteriophages and dairy fermentations","volume":"2","author":"Marco","year":"2012","journal-title":"Bacteriophage"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev-food-060721-015928","article-title":"Bacteriophages in the dairy industry: A problem solved?","volume":"14","author":"Mahony","year":"2023","journal-title":"Annu. Rev. Food Sci. Technol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41575-020-00390-5","article-title":"The International Scientific Association for Probiotics and Prebiotics consensus statement on fermented foods","volume":"18","author":"Marco","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wu, Q., Li, L., Xiang, P., Zhang, T., Peng, L., Zou, L., and Li, Q. (2023). Phages in fermented foods: Interactions and applications. Fermentation, 9.","DOI":"10.3390\/fermentation9030201"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e00201-24","DOI":"10.1128\/msystems.00201-24","article-title":"Dynamics of the viral community on the surface of a French smear-ripened cheese during maturation and persistence across production years","volume":"9","author":"Paillet","year":"2024","journal-title":"mSystems"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ka\u017amierczak, Z., Majewska, J., Miernikiewicz, P., Mi\u0119dzybrodzki, R., Nowak, S., Harhala, M., Lecion, D., K\u0119ska, W., Owczarek, B., and Ciekot, J. (2021). Immune response to therapeutic staphylococcal bacteriophages in mammals: Kinetics of induction, immunogenic structural proteins, natural and induced antibodies. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.639570"},{"key":"ref_42","first-page":"656","article-title":"Harnessing bacteriophages: A promising approach to combat foodborne pathogen biofilms","volume":"13","author":"Kinanti","year":"2024","journal-title":"Int. J. Agric. Biosci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.chom.2019.05.001","article-title":"Dynamic modulation of the gut microbiota and metabolome by bacteriophages in a mouse model","volume":"25","author":"Hsu","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hyman, P. (2019). Phages for phage therapy: Isolation, characterization, and host range breadth. Pharmaceuticals, 12.","DOI":"10.3390\/ph12010035"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Mirzaei, M.K., and Nilsson, A.S. (2015). Isolation of phages for phage therapy: A comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127606"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"fuaf061","DOI":"10.1093\/femsre\/fuaf061","article-title":"Phage cocktails: State-of-the-art technologies and strategies for effective design","volume":"50","author":"Kaneko","year":"2026","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3354\/ame013019","article-title":"Theoretical models for the control of bacterial growth rate, abundance, diversity and carbon demand","volume":"13","author":"Thingstad","year":"1997","journal-title":"Aquat. Microb. Ecol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1128\/MMBR.00034-09","article-title":"Trade-offs between competition and defense specialists among unicellular planktonic organisms: The killing the winner hypothesis revisited","volume":"74","author":"Winter","year":"2010","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"10771","DOI":"10.1073\/pnas.1305923110","article-title":"Bacteriophage adhering to mucus provide a non-host-derived immunity","volume":"110","author":"Barr","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cis.2017.05.014","article-title":"Formulation, stabilisation and encapsulation of bacteriophage for phage therapy","volume":"249","author":"Malik","year":"2017","journal-title":"Adv. Colloid Interface Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e01979-20","DOI":"10.1128\/AEM.01979-20","article-title":"Encapsulation and delivery of therapeutic phages","volume":"87","author":"Loh","year":"2021","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e00926-19","DOI":"10.1128\/IAI.00926-19","article-title":"Fitness trade-offs resulting from bacteriophage resistance potentiate synergistic antibacterial strategies","volume":"88","author":"Mangalea","year":"2020","journal-title":"Infect. Immun."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Liu, J.Y., Lin, T.L., Chiu, C.Y., Hsieh, P.F., Lin, Y.T., Lai, L.Y., and Wang, J.T. (2022). Decolonization of carbapenem-resistant Klebsiella pneumoniae from the intestinal microbiota of model mice by phages targeting two surface structures. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.877074"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e01984-19","DOI":"10.1128\/mBio.01984-19","article-title":"Bacteriophage adherence to mucus mediates preventive protection against pathogenic bacteria","volume":"10","author":"Almeida","year":"2019","journal-title":"mBio"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Arellano, S.N., Gonz\u00e1lez-G\u00f3mez, J.P., Gomez-Gil, B., Gonz\u00e1lez-\u00c1vila, M., Palomera-Hern\u00e1ndez, J.R., Barr\u00f3n-Cabrera, E., Vergara-Jim\u00e9nez, M.d.J., and Chaidez, C. (2025). A two-phage cocktail modulates gut microbiota composition and metabolic profiles in an ex vivo colon model. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26062805"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41467-024-47192-w","article-title":"Phage-specific immunity impairs efficacy of bacteriophage targeting vancomycin-resistant Enterococcus in a murine model","volume":"15","author":"Berkson","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Mendes, B.G., Duan, Y., and Schnabl, B. (2022). Immune response of an oral Enterococcus faecalis phage cocktail in a mouse model of ethanol-induced liver disease. Viruses, 14.","DOI":"10.3390\/v14030490"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1128\/AEM.00246-08","article-title":"Microencapsulation of bacteriophage Felix O1 into chitosan-alginate microspheres for oral delivery","volume":"74","author":"Ma","year":"2008","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"9785","DOI":"10.1038\/s41467-025-65498-1","article-title":"In situ gut microbiota editing: Enhancing therapeutic efficacy for bacterial colitis by compatible oral hydrogel microspheres with phages","volume":"16","author":"Yang","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/1462-2920.13574","article-title":"Oral application of Escherichia coli bacteriophage: Safety tests in healthy and diarrheal children from Bangladesh","volume":"19","author":"Sarker","year":"2017","journal-title":"Environ. Microbiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","article-title":"Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease","volume":"575","author":"Duan","year":"2019","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut-liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s42003-022-03001-y","article-title":"Characterization of phage resistance and phages capable of intestinal decolonization of carbapenem-resistant Klebsiella pneumoniae in mice","volume":"5","author":"Fang","year":"2022","journal-title":"Commun. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Buttimer, C., Sutton, T., Colom, J., Murray, E., Bettio, P.H., Smith, L., Bolocan, A.S., Shkoporov, A., Oka, A., and Liu, B. (2022). Impact of a phage cocktail targeting Escherichia coli and Enterococcus faecalis as members of a gut bacterial consortium in vitro and in vivo. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.936083"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2208504","DOI":"10.1080\/19490976.2023.2208504","article-title":"Fecal virome transfer improves proliferation of commensal gut Akkermansia muciniphila and unexpectedly enhances the fertility rate in laboratory mice","volume":"15","author":"Rasmussen","year":"2023","journal-title":"Gut Microbes"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Xie, Y., Wahab, L., and Gill, J.J. (2018). Development and validation of a microtiter plate-based assay for determination of bacteriophage host range and virulence. Viruses, 10.","DOI":"10.3390\/v10040189"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1093\/infdis\/jiaa497","article-title":"The gut microbiome as a reservoir for antimicrobial resistance","volume":"223","author":"Anthony","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Merabishvili, M., Pirnay, J.P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J., and Van Parys, L. (2009). Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0004944"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Dufour, N., Delattre, R., and Debarbieux, L. (2024). High-throughput bacteriophage testing with potency determination: Validation of an automated pipetting and phage drop-off method. Biomedicines, 12.","DOI":"10.3390\/biomedicines12020466"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Panteleev, V., Kulbachinskiy, A., and Gelfenbein, D. (2025). Evaluating phage lytic activity: From plaque assays to single-cell technologies. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1659093"},{"key":"ref_71","unstructured":"U.S. Food and Drug Administration (2026, June 30). Notifications for Structure\/Function and Related Claims in Dietary Supplement Labeling, Available online: https:\/\/www.fda.gov\/food\/information-industry-dietary-supplements\/notifications-structurefunction-and-related-claims-dietary-supplement-labeling."},{"key":"ref_72","unstructured":"U.S. Food and Drug Administration (2026, June 30). GRAS Notice No. GRN 000672: Preparation Containing Five Bacterial Monophages Specific to Shigella spp., Available online: https:\/\/www.fda.gov\/files\/food\/published\/GRAS-Notice-000672---Preparation-containing-five-bacterial-monophages-specific-to-Shigella-spp..pdf."},{"key":"ref_73","unstructured":"U.S. Food and Drug Administration (2026, June 30). GRAS Notice No. GRN 000724: Preparation Containing Bacteriophages Specific to Shiga Toxin-Producing Escherichia coli, Available online: https:\/\/www.cfsanappsexternal.fda.gov\/scripts\/fdcc\/?set=GRASNotices&id=724."},{"key":"ref_74","unstructured":"Court of Justice of the European Union (2026, July 01). Case C-745\/22, Micreos Food Safety BV v EFET, Judgment of 22 February 2024. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX%3A62022CJ0745."},{"key":"ref_75","unstructured":"International Council for Harmonisation (2026, June 30). ICH Q8(R2): Pharmaceutical Development. Available online: https:\/\/database.ich.org\/sites\/default\/files\/Q8_R2_Guideline.pdf."},{"key":"ref_76","unstructured":"U.S. Food and Drug Administration (2026, June 30). Q8(R2) Pharmaceutical Development: Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/q8r2-pharmaceutical-development."},{"key":"ref_77","unstructured":"European Medicines Agency (2026, June 30). ICH Q8(R2): Pharmaceutical Development\u2014Scientific Guideline, Available online: https:\/\/www.ema.europa.eu\/en\/ich-q8-r2-pharmaceutical-development-scientific-guideline."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/8\/907\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:10:04Z","timestamp":1787044204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/8\/907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":78,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["v18080907"],"URL":"https:\/\/doi.org\/10.3390\/v18080907","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}